Herzig Daniela S, Guo Yin, Fang Geping, Toliver-Kinsky Tracy E, Sherwood Edward R
Crit Care. 2012 Sep 19;16(5):R168. doi: 10.1186/cc11642.
In our previous studies we demonstrated that CXC chemokine receptor 3 (CXCR3) participates in the regulation of lymphocyte trafficking during cecal ligation and puncture (CLP)-induced sepsis. In this study, we evaluated the effects of treatment with anti-CXCR3 immunoglobulin (IgG) and antibiotics on outcome during septic shock caused by CLP.
C57BL/6J mice were treated with neutralizing IgG against CXCR3 plus Primaxin either 24 hours prior to, 2 hours after or 6 hours after CLP. Control mice received nonspecific IgG plus Primaxin in the same regimen. Survival, core body temperature, bacterial clearance and systemic cytokine production were evaluated.
Our results show that treatment with anti-CXCR3 IgG plus Primaxin significantly improved survival when administered 24 hours prior to CLP (50% vs. 10%), 2 hours after CLP (55% vs. 10%) or 6 hours after CLP (55% vs. 25%) compared with mice receiving nonspecific IgG plus Primaxin. Treatment with anti-CXCR3 plus Primaxin 24 hours prior to CLP attenuated hypothermia and IL-6 and macrophage inflammatory protein 2 (MIP-2) production but did not alter bacterial clearance. Treatment with anti-CXCR3 IgG and Primaxin 2 hours after CLP did not improve bacterial clearance and systemic cytokine production compared with mice treated with IgG and Primaxin, whereas 6 hours after CLP the bacterial clearance and IL-6 and MIP-2 concentrations, both in plasma and peritoneal lavage fluid, were significantly improved in mice receiving anti-CXCR3 IgG and Primaxin compared with mice that only received nonspecific IgG and Primaxin.
The results from this study indicate that neutralization of CXCR3 prior to, 2 hours after or 6 hours after the initiation of CLP-induced septic shock improves survival and attenuates CLP-induced inflammation and physiologic dysfunction.
在我们之前的研究中,我们证明了CXC趋化因子受体3(CXCR3)参与了盲肠结扎穿孔(CLP)诱导的脓毒症期间淋巴细胞运输的调节。在本研究中,我们评估了抗CXCR3免疫球蛋白(IgG)和抗生素治疗对CLP所致感染性休克结局的影响。
C57BL/6J小鼠在CLP前24小时、CLP后2小时或CLP后6小时接受抗CXCR3中和IgG加哌拉西林/他唑巴坦治疗。对照小鼠按相同方案接受非特异性IgG加哌拉西林/他唑巴坦治疗。评估生存率、核心体温、细菌清除率和全身细胞因子产生情况。
我们的结果表明,与接受非特异性IgG加哌拉西林/他唑巴坦的小鼠相比,在CLP前24小时(50%对10%)、CLP后2小时(55%对10%)或CLP后6小时(55%对25%)给予抗CXCR3 IgG加哌拉西林/他唑巴坦治疗可显著提高生存率。CLP前24小时用抗CXCR3加哌拉西林/他唑巴坦治疗可减轻体温过低以及IL-6和巨噬细胞炎性蛋白2(MIP-2)的产生,但不改变细菌清除率。与用IgG和哌拉西林/他唑巴坦治疗的小鼠相比,CLP后2小时用抗CXCR3 IgG和哌拉西林/他唑巴坦治疗并未改善细菌清除率和全身细胞因子产生情况,而CLP后6小时,与仅接受非特异性IgG和哌拉西林/他唑巴坦的小鼠相比,接受抗CXCR3 IgG和哌拉西林/他唑巴坦的小鼠血浆和腹腔灌洗液中的细菌清除率以及IL-6和MIP-2浓度均显著改善。
本研究结果表明,在CLP诱导的感染性休克开始前、后2小时或后6小时中和CXCR3可提高生存率,并减轻CLP诱导的炎症和生理功能障碍。